The neuroendocrine (NE) cells represent the third cell population in the normal prostate. Results of several clinical studies strongly indicate that the NE cell population is greatly increased in prostate carcinomas during androgen ablation therapy that correlates with hormone-refractory growth and poor prognosis. However, the mechanism of NE cell enrichment in prostate carcinoma remains an enigma. We investigated the molecular mechanism by which androgen-sensitive C-33 LNCaP human prostate cancer cells become NE-like cells in an androgen-reduced environment, mimicking clinical phenomenon. In the androgen-depleted condition, androgen-sensitive C-33 LNCaP cells gradually acquired the NE-like morphology and expressed an increased level of neuron-specific enolase (NSE), a classical marker of neuronal cells. Several NE-like subclone cells were established. Biochemical characterizations of these subclone cells showed that receptor-type protein-tyrosine phosphatase alpha (RPTPa) is elevated and ERK is constitutively activated, several folds higher than that in parental cells. In androgen-depleted condition, PD98059, an MEK inhibitor, could efficiently block not only the activation of ERK, but also the acquisition of the NE-like morphology and the elevation of NSE in C-33 LNCaP cells. In RPTPa cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE was elevated. In those cells in the presence of PD98059, the ERK activation and NSE elevation were abolished, following a dose-response fashion. Additionally, in constitutively active MEK mutant cDNA-transfected C-33 LNCaP cells, ERK was activated and NSE level was elevated, and cells obtained the NE-like phenotype. Our data collectively indicated that RPTPa signaling via ERK is involved in the NE transdifferentiation of androgen-sensitive C-33 LNCaP human prostate cancer cells in the androgen-depleted condition.
Introduction
Prostate cancer is the most commonly diagnosed malignant disease in men and the second leading cause of male cancer death (Greenlee et al., 2001) . Initially, the proliferation of prostate cancer cells depends on androgens. Therefore, androgen ablation therapy by surgery and/or drugs is the treatment most often used for metastasized prostate cancers. However, in most cases, the cancer eventually relapses and its growth becomes androgen-independent. Currently, treatment of hormone-refractory prostate cancers has had only limited efficacy. It is well recognized that the progression of prostate cancer in the androgen-ablated condition relies on several factors besides alterations of androgen receptors (Greenlee et al., 2001) . It is thus important to delineate the molecular mechanism of androgen-independent growth.
NE cells are the third cell population in the normal prostate gland, and their functional role in prostate cancer progression has received considerable attention in basic and clinical studies recently (Shen et al., 1997; di Sant'Agnese, 1998a, b; Qiu et al., 1998; Abrahamsson, 1999a; Zi and Agarwal, 1999; Cox et al., 2000) . It is proposed that, in normal prostate, NE cells play a role in regulating prostate cell growth and differentiation in an androgen-independent manner (Gkonos et al., 1995; Bonkhoff and Remberger, 1996) . In prostate carcinomas, especially under androgen-ablation therapy, the NE cell population is increased by several folds with scattered clusters among other malignant cells (Abrahamsson, 1999a, b) . Those tumors with an increased NE cell population are often more aggressive and eventually become androgen-independent (Cohen et al., 1991; Tarle et al., 1994; di Sant'Agnese and Cockett, 1996; Theodorescu et al., 1997; Abrahamsson, 1999a, b) . For example, carcinoid tumors or small-cell carcinomas are proposed to be prostate carcinomas with total NE differentiation and have a very aggressive course (Almagro et al., 1986; Tetu et al., 1987) . The functional role of NE cells in prostate carcinomas may be in part related to the fact that NE cells express and secrete a variety of factors including neurohormones that have potent growth-stimulating capabilities (Bologna et al., 1989; Seuwen and Pouyssegur, 1990; Iwamura et al., 1994; Shah et al., 1994; Seethalakshmi et al., 1997) . It is thus proposed that NE cells can promote the proliferation of adjacent carcinoma cells in an androgen-depleted condition, leading to androgen-independent progression of the cancer (Bonkhoff et al., 1991; Bonkhoff, 1998) . This notion is supported by the observations that the proliferation index of proximate cancer cells surrounding the NE cells is higher than that of distal cancer cells (Cockett et al., 1993; Abrahamsson, 1999b) . Furthermore, those NE factors can stimulate androgen-independent growth of prostate cancer cells in culture (Jongsma et al., 2000) . Thus, it is imperative to delineate the functional role of NE cells in prostate malignancy.
Although the NE cell population is enriched during androgen ablation or antiandrogen therapy (Abrahamsson and Lilja, 1989) , the molecular mechanism of NE cell enrichment remains an enigma. Noordzij et al. (1996) have demonstrated that short-term androgen withdrawal induces rapid NE differentiation in a xenograft animal model. In the cell culture system, androgen depletion and a variety of pharmacological reagents including cytokines can induce NE transdifferentiation of different prostate cancer cells (Shen et al., 1997; Qiu et al., 1998; Zi and Agarwal, 1999; Cox et al., 2000; Zelivianski et al., 2001) . For example, in response to an elevated intracellular cAMP level by treating cells with b-adrenergic receptor agonists, epinephrine and isoproterenol, or with the adenylate cyclase activator forskolin, LNCaP and PC-3 human prostate cancer cells transdifferentiate into NE-like cells by acquiring NE characteristics, including morphology with neurite processes and elevated expression of NSE, a classical marker of neuronal cells (Bang et al., 1994; Cox et al., 1999; Zelivianski et al., 2001) . Cytokines, including IL-6 (Qiu et al., 1998; Mori et al., 1999) and IL-1b (Diaz et al., 1998) , can also induce LNCaP cells to transdifferentiate into NE-like cells. Thus, multiple pathways may be involved in NE differentiation of different prostate cancer cells in culture . However, the biological relevance to clinical prostate cancer and the molecular mechanism of transdifferentiation induced by those pharmacological reagents remain for further investigation.
Activation of the ERK cascade is a critical mechanism for transcriptional regulation by extracellular signals and a key regulatory pathway of mammalian cell proliferation (Seger and Krebs, 1995; Treisman, 1996; Lewis et al., 1998) . Several lines of evidence indicate that the ERK pathway is also involved in embryonic development and cell differentiation (Seger and Krebs, 1995; Ferrell, 1996; Treisman, 1996; Schaeffer and Weber, 1999) . For example, activation of MEK and ERK is essential for eye development in Drosophila (Lewis et al., 1998) , vulval development in C. elegans (Sundaram and Han, 1996) , and mesoderm induction in Xenopus embryos (Umbhauer et al., 1995) . In the presence of NGF, PC-12 rat pheochromocytoma cells develop neurite outgrowth and express neuronal markers (Lewis et al., 1998) . Studies utilizing the MEK inhibitor PD98059 and its dominant-negative mutant have shown that NGF-induced neuronal differentiation of PC-12 cells requires sustained activation of ERK (Cowley et al., 1994; Marshall, 1995; Pang et al., 1995) . Conversely, in the absence of NGF, the expression of a constitutively activated MEK mutant is sufficient to induce neuronal differentiation of PC-12 cells (Cowley et al., 1994) . Furthermore, phorbol ester 12-o-tetradecanoylphorbol-13-acetate can induce differentiation of K562 human erythroleukemia cells into megakaryocytes, and the process is blocked by PD98059 (Whalen et al., 1997) . The sustained activation of the ERK pathway by a constitutively active MEK mutant can also induce the megakaryocytic differentiation of these K562 cells (Racke et al., 1997; Whalen et al., 1997) . In addition, prolonged activation of ERK is required for macrophage-like differentiation of TF-1a human myeloid leukemic cells (Hu et al., 2000) and terminal muscle differentiation of C2 fibroblast cells (Bennett and Tonks, 1997; Gredinger et al., 1998) . Thus, constitutively activated ERK plays a critical role in cell differentiation.
RPTPa is a member of the transmembrane subfamily of PTPs with wide expression in human tissues, especially in neurons and their processes, and is involved in several pathways of cell proliferation and differentiation. For example, RPTPa can downregulate insulinincreased prolactin gene activity by dephosphorylating insulin receptor (Lammers et al., 1997; Jacob et al., 1998) . RPTPa is also involved in regulating Kv-1.2 channel activity (Tsai et al., 1999) and the integrinmediated response in fibroblasts as well as in cell adhesion through interaction with contactin (Zeng et al., 1999) . Furthermore, RPTPa can activate cSrc and is involved in neuronal differentiation of ES and EC cells (den Hertog et al., 1993; van Inzen et al., 1996; Zheng et al., 2000) . Overexpression of RPTPa in rat embryo fibroblasts leads to the activation of ERK and cJun (Zheng and Pallen, 1994) . Thus, RPTPa plays a critical role in numerous differentiation activities in different cell types. Although RPTPa is expressed in normal prostate cells and prostate cancer cells (Zelivianski et al., 2000 , the functional role of RPTPa in human prostate cells remains to be studied.
In this communication, we investigated the signal transduction pathway that is involved in NE transdifferentiation of human prostate cancer cells. Since multipathways can be involved in NE transdifferentiation of different prostate cancer cells , we focused on studying the transdifferentiation of androgen-sensitive C-33 LNCaP cells induced by androgen depletion, resembling the clinical phenomenon in androgen ablation therapy. We established several NE-like subclones and analysed the molecular mechanism of this NE transdifferentiation. Our data clearly showed that RPTPa is elevated and ERK is activated in these NE-like subclone cells. We subsequently determined that RPTPa signaling via ERK is involved in the NE transdifferentiation of androgen-sensitive C-33 LNCaP prostate cancer cells in an androgen-depleted condition.
Results

Establishment of NE-like subclone cells
We induced transdifferentiation of androgen-sensitive C-33 LNCaP parental cells into NE-like cells by the androgen-depletion approach. When C-33 LNCaP cells were maintained in an androgen-depleted medium, the cell growth diminished and the cell morphology changed gradually. About 2 weeks later, those cells acquired a neuronal-like phenotype as characterized by small cell bodies and multiple elongated, irregular processes (data not shown). In contrast, control LNCaP parental cells exhibited the epithelial morphology.
The population of NE-like cells was maintained continuously in the androgen-depleted medium as described above. A single cell was isolated by a cylinder and propagated. After approximately 6 months, several subclone cells became independent cell lines and exhibited a NE-like phenotype. Two subcloned cell lines, designated as NE-1.3 and NE-1.8 (Figure 1a) , were randomly chosen for further study. As shown in Figure 1a , cells from these two clones clearly exhibited neuronal-like morphology. The expression of NSE, a classical marker of neuronal cells, was initially analysed. Interestingly, C-33 LNCaP cells expressed NSE, although the level was very low (Figure 1b ; Zelivianski et al., 2001) . Compared to C-33 LNCaP cells, NE subclone cells expressed significantly higher levels of NSE by approximately 20-fold (Figure 1b) .
Effect of androgen depletion on NE differentiation was determined. During the initial maintenance of C-33 LNCaP cells in the androgen-reduced medium, other sets of cells were exposed to DHT in the presence or absence of Casodex, a DHT antagonist. As shown in Figure 1c , DHT decreased the elevated NSE level in the androgen-depleted condition, while Casodex effectively antagonized the effect of DHT, indicating that the elevation of NSE induced by the steroid-reduced condition is indeed due to androgen depletion. To explore whether the NE differentiation of these subclone cells by androgen depletion is a reversible process, as described in a previous report of the cAMP treatment (Cox et al., 1999) , the NE subclone cells were cultured in the regular medium used for C-33 LNCaP cells which are androgen-sensitive . Over a period of 3 months, neither the morphology nor the NSE level of these NE-like subclone cells was restored to that of the C-33 LNCaP cells (data not shown), suggesting that the NE-like phenotype of these cells can be propagated perfectly in culture. These NE subclone cells are thus suitable for further study.
To further examine the possibility that C-33 LNCaP cells contain a minor population of NE cells which gradually become the major population during the process of androgen depletion, immunofluorescence staining was performed to determine the expression of NSE in NE-1.3 and NE-1.8 cells, comparing with that in C-33 LNCaP cells maintained in regular condition. An additional control of LNCaP-SR cells, that is, C-33 parental cells precultured in an androgen-deprived condition for 2 weeks, was included. The results (Figure 2) clearly showed that the expression of NSE is similar and very low in the total population of C-33 LNCaP cells, whereas the NSE expression increases in LNCaP-SR cells, as shown in our previous publication Total cellular proteins from C-33 LNCaP and NE subclone cells were separated by SDS-PAGE, and the expression of NSE was analysed by Western blotting using the anti-NSE monoclonal Ab. As an internal control, the level of b-actin was examined. (c) Androgen-sensitive C-33 LNCaP cells were initially seeded in regular medium for 2 days. At 48 h after steroid starvation, cells were fed with fresh steroid-reduced (SR) medium containing 10 mm Casodex, 10 nm DHT, or DHT/Casodex combination. Control cells were maintained in regular medium. The level of NSE was detected using the anti-NSE Ab. As an internal control, the level of b-actin was examined . Two NE subclone cells expressed high levels of NSE. Furthermore, a similar phenotype as well as NSE expression was observed in the major population of C-33 LNCaP cells. After 2 weeks of androgen depletion, the major population of LNCaP cells, rather than a small subpopulation of cells, changed their morphology and displayed the NE phenotype, that is, long and/or multi-processings ( Figure 2 ). These observations indicated that the process of NE transdifferentiation occurred essentially in the homogeneous cell population, but not the selection of a small subpopulation after long-term androgen depletion.
Expression of RPTPa in NE subclone cells
Since RPTPa plays an important role in neuronal differentiation (den Hertog et al., 1993; van Inzen et al., 1996) , and has low level of expression in C-33 LNCaP cells (Zelivianski et al., 2000) , the expression of RPTPa in the established NE subclone cells was analysed. As shown in Figure 3a , the protein level of RPTPa in both NE subclone cells was elevated by over fivefold, higher than that in C-33 LNCaP cells. 
Sustained activation of ERK in NE subclone cells
Since sustained activation of ERK is involved in various cell differentiation and ERK is downstream of RPTPa signaling (Zheng and Pallen, 1994) , we analysed whether ERK was activated in NE subclone cells. As shown in Figure 4a , in NE-1.3 and 1.8 cells, both ERK1 and ERK2 were highly activated, as indicated by their phosphorylation levels. In contrast, the phosphorylation level of ERKs in the C-33 LNCaP cells was very low, although it was detectable after a prolonged exposure with the ECL method (data not shown). In all these cells, the protein levels of p42 and p44 ERKs were very similar. These results clearly showed that both ERK1 and ERK2 in NE subclone cells are constitutively activated.
To examine whether the ERK upstream kinase MEK was also activated in NE subclone cells, the activation status of MEK was analysed by Western blotting using an Ab against phosphorylated MEK protein at Ser-217/ 221. As shown in Figure 4b , MEK was highly phosphorylated in NE subclone cells with similar levels of MEK protein in all the three cells, indicating that MEK was constitutively activated in NE subclone cells, but not in C-33 LNCaP parental cells. To determine the functional role of MEK activation in ERK phosphorylation, a MEK inhibitor PD98059 was utilized. In the presence of PD98059, the phosphorylation of ERK in NE-1.3 cells was rapidly abolished (Figure 4c ), indicating that activation of MEK was required for the downstream activation of ERK in NE subclone cells. Thus, in prostate NE cells, RPTPa is elevated, and MEK as well as ERK are activated.
Effect of MEK inhibitor on NE differentiation of LNCaP cells in an androgen-depleted condition
To investigate the functional role of ERK in NE transdifferentiation of C-33 LNCaP cells induced by androgen depletion, we examined the effect of PD98059 on this process. C-33 LNCaP cells were plated and grown in RPMI 1640 medium supplemented with 5% FBS for 48 h. NE differentiation was induced by maintaining those cells in an androgen-depleted condition in the presence or absence of PD98059.
In the absence of PD98059, the morphology of C-33 LNCaP cells changed gradually in androgen-depleted medium. The distinct NE-like morphology became apparent after approximately 10 days. Multiple elongated neurite outgrowths with a small cell body could be seen over a longer period in the androgendepleted condition (Figure 1a, 5a) . Nevertheless, in the presence of PD98059, this morphological change was essentially abolished (Figure 5a) . Furthermore, as shown in Figure 5b , ERK was activated in the cells grown in androgen-depleted medium, while PD98059 abolished the activation of ERK induced by the androgen depletion. Interestingly, the activation of ERK correlated with the expression level of NSE in those cells (Figure 5b ). PD98059 effectively reduced more than 50% the elevated level of NSE induced by androgen depletion (Figure 5b ). These results showed that MEK inhibitor can effectively block the NE phenotype as well as the elevated NSE level induced by androgen depletion in C-33 LNCaP cells.
Effect of RPTPa overexpression on transdifferentiation of C-33 LNCaP cells
To determine the functional role of RPTPa in the transdifferentiation process of C-33 LNCaP cells, we transfected those cells with a cDNA encoding the wildtype murine RPTPa tagged with an HA epitope (den Hertog et al., 1993) . As shown in Figure 6a , the expression of exogenous RPTPa was confirmed by immunoblotting with an Ab against the HA epitope at the position of approximately 150 kDa, which comigrated with a protein recognized by an Ab against murine RPTPa (den Hertog et al., 1994) . Interestingly, the commercially available RPTPa Ab that was raised against the first phosphatase domain of human RPTPa did not react with the exogenous murine RPTPa (data not shown). Nevertheless, this commercial Ab reacted with the endogenous RPTPa at the 130 kDa position (Figure 6a ; Zelivianski et al., 2001 ). The expression level of endogenous RPTPa was not altered after the expression of exogenous RPTPa (Figure 6a ). Importantly, in those transfected cells, the expression level of NSE increased, following a dose response of exogenous RPTPa expression (Figure 6a, middle) . Furthermore, in those same cells, the phosphorylation level of p42 ERK2 was elevated and followed a dose-dependent fashion (Figure 6a ), while the activation of p44 ERK1 could be detected after a prolonged exposure (data not shown). To clarify the specificity of this RPTPa action, we analysed the effect on the expression of NSE and the activation of ERK by the wild-type PAcP cDNA, a prostate-specific PTP (Lin and Clinton, 1986; Zhang et al., 2001) . As shown in Figure 6b , overexpression of PAcP had no effect on NSE expression or ERK activation, as indicated by the phosphorylation level of p42 ERK.
To determine RPTPa signaling via MEK and ERK leading to NSE elevation, C-33 LNCaP cells were transfected with RPTPa cDNA in the presence or absence of PD98059. As shown in Figure 6c (top), in the absence of PD98059 after RPTPa cDNA transfection, ERK2 was greatly activated and this effect correlated with the elevated level of NSE (Figure 6c , bottom) and the activation of MEK (data not shown). In the presence of PD98059, the activation of ERK as well as elevation of NSE was decreased, following a dose-dependent fashion (Figure 6c ). Collectively, these data indicate that overexpression of RPTPa in androgen-sensitive C-33 LNCaP cells leads to the activation of ERK and an elevation of NSE. Furthermore, this effect is observed only for the wild-type RPTPa, but not for PAcP.
Effect of increased RPTPa expression on NE transdifferentiation of C-33 LNCaP cells was further examined utilizing the RPTPa-Y789F mutant. It is reported that phosphorylation at tyrosine 789 (pY789) of RPTPa is important for RPTPa interaction with Grb-2 and c-Src, leading to downstream signaling regulation (den Hertog et al., 1994; Zheng et al., 2000) . We analysed if Y789 at RPTPa is required for mediating its effects on NE differentiation in C-33 LNCaP cells since this mutant retains its PTP activity. C-33 LNCaP cells were transiently transfected with the wild-type or the Y789F mutant of RPTPa cDNA. As shown in Figure 7a To determine further whether the activation of ERK alone is sufficient to induce the acquisition of NE characteristics in C-33 LNCaP cells, these cells were transfected with rat cDNAs encoding the HA-tagged wild-type MEK1 and a constitutively activated mutant (S218D/S222D), respectively. Control cells were transfected with the vector alone. As shown in Figure 8a , expression of the exogenous wildtype and mutant MEK1 proteins was readily detected by Western An equal amount of cellular protein was separated by SDS-PAGE. The expression of PAcP, NSE, and phosphorylation level of ERK was analysed by immunoblotting using appropriate Abs. The level of b-actin was used as a loading control. The low level of endogenous PAcP in the vector-alone transfected cells was due to a short exposure. (c) C-33 LNCaP cells were transfected with RPTPa cDNA or vector alone. At 24 h after transfection, the cells were fed with the fresh regular medium containing different concentrations of inhibitor as indicated and maintained for 48 h. Total cellular proteins were separated by SDS-PAGE and phosphorylation level of ERK was analysed using Ab specific to phospho-ERK. The expression levels of NSE and b-actin, and protein levels of ERKs were detected with appropriate Abs blotting with anti-HA and anti-MEK Abs, respectively. In cells that were transfected with the activated MEK1 mutant cDNA, both ERK1 and ERK2 were highly activated, as indicated by their phosphorylation levels (Figure 8a, middle) . In contrast, the cells transfected with the wild-type MEK1 cDNA or the vector alone had a very low level of ERK phosphorylation, although the wild-type MEK1-transfected cells had a slightly higher phosphorylation level than the vector-transfected cells after prolonged exposure (data not shown). In cells transfected with the activated MEK1 mutant cDNA, the NSE level was elevated, higher than in the cells transfected with either the vector alone or the wild-type MEK1 cDNA (Figure 8a, bottom) . These results The effect of ERK activation on the phenotype of C-33 LNCaP cells was also examined. C-33 LNCaP cells were transfected with a GFP expression vector alone or the GFP vector containing the wild-type MEK cDNA or a constitutively activated MEK cDNA. The morphology of the transfected cells was visualized under a fluorescence microscope. We observed that in the active MEK plus GFP transfection, over 60% GFP-positive cells exhibited the NE phenotype with multibranched processes (Figure 8b) . Nevertheless, none of the GFPpositive cells showed the NE phenotype after transfection with the GFP vector alone or the vector containing the wild-type MEK cDNA (Figure 8b) . Thus, activation of ERK correlates with an NE-like phenotype in androgen-sensitive C-33 LNCaP cells in which NSE expression is elevated.
Discussion
Due to the potential importance of NE cells in advanced prostate carcinogenesis, we investigated the molecular pathway of androgen depletion-induced NE transdifferentiation of androgen-sensitive prostate cancer cells, although multiple pathways and mechanisms can be involved in NE transdifferentiation of prostate cancer cells (Bang et al., 1994; Diaz et al., 1998; Qiu et al., 1998; Burchardt et al., 1999; Cox et al., 1999; Mori et al., 1999; Deeble et al., 2001; Lee et al., 2001; Zelivianski et al., 2001) . In an androgen-depleted condition, androgen-sensitive C-33 LNCaP cells gradually acquired an NE-like morphology and expressed an increased level of NSE. Results of further experiments utilizing androgen and Casodex clearly showed that this transdifferentiation occurred via an androgen-depleted process. We have established several NE subclone cells and found that their biochemical properties and the phenotype are irreversible, since the NE phenotype is maintained even after long-term culturing in the normal growth medium (data not shown). These subclone cells thus resemble NE cells in clinical specimens, that is, the 'terminally differentiated' cells, and differ from NE cells in a previous study that utilized cAMP induction (Cox et al., 1999) . These subclone cells therefore can serve as a useful cell model system in further biochemical characterizations.
In NE subclone cells, in addition to the increased level of NSE expression, we found that the protein level of RPTPa is elevated. Our previous data showed that RPTPa mRNA (Zelivianski et al., 2000) and protein ) levels are increased in LNCaP cells after short-term steroid withdrawal without known biological implications. Transient transfection clearly demonstrates that overexpression of the wild-type RPTPa results in activation of ERK (Figures 6a, c, 7a ) as well as elevation of NSE level in a dose-dependent fashion (Figures 6a, c, 7a ). This RPTPa effect is efficiently blocked by PD98059 (Figure 6c) . Conversely, overexpression of PAcP (Figure 6b ) or RPTPa-Y789F mutant (Figure 7a ) has no effect on NSE level. Moreover, overexpression of RPTPa in androgen-independent PC-3 prostate cancer cells does not induce the activation of ERK or the elevation of NSE expression (data not shown). The activation of ERK by RPTPa in C-33 LNCaP cells is therefore similar to its effect on ERK activation in rat embryo fibroblasts (Zheng and Pallen, 1994) , and also similar to its functional role in neuronal differentiation (den Hertog et al., 1993; van Inzen et al., 1996) . The relatively small increase in NSE level with RPTPa cDNA transfection (Figures 6a, 7a ), compared with the high level of NSE in NE subclone cells (Figure 1b) , could be caused in part by the low transfection efficiency of C-33 LNCaP cells (Ruokonen et al., 1996; Zelivianski et al., 1998; Fronsdal et al., 2000) . Similarly, we observed an overall low number of GFP-positive cells in transient transfected cells (Figures  7b, 8b) . Taken together, these data indicate that RPTPa plays an important role in the NE differentiation process of androgen-sensitive LNCaP prostate cancer cells in androgen-depleted environment.
The functional role of RPTPa in androgen-independent growth and NE differentiation of prostate cancer cells deserves careful considerations. Results of previous studies indicate that elevated expression of RPTPa correlates with NE differentiation of androgen-sensitive human prostate cancer cells in steroid-depleted condition . Our data in this communication clearly show that the expression of RPTPa is elevated in androgen-depleted C-33 LNCaP cells as well as in NE subclone cells, correlating with ERK activation and NSE expression. Furthermore, the wild-type RPTPa cDNA transfection led to ERK activation and NSE elevation. Nevertheless, the molecular signaling of RPTPa via MEK/ERK pathway to induce NE differentiation remains an enigma.
It has been shown that Grb-2 and c-Src could interact with RPTPa (den Hertog et al., 1994; Zheng et al., 2000) . Since the association of RPTPa with Grb-2 attenuates the Grb-2-mediated signaling (den Hertog et al., 1994) , RPTPa signaling could not be mediated by Grb-2 for downstream activation in NE differentiation. We therefore propose that RPTPa via c-Src activates the MEK/ERK pathway to induce NE differentiation. The notion is supported by observations that RPTPa via its phosphotyrosine 789 (pY789) interacts with c-Src and dephosphorylates its pY527, the negative regulatory site of c-Src, which leads to activate c-Src activity and its downstream signaling (Zheng et al., 2000) . Mutation of Y789 (Y789F) at RPTPa abolishes the RPTPa-Src interaction, although this mutant retains its PTP activity, and subsequently abrogates the capability of RPTPa to activate c-Src (Zheng et al., 2000) . Thus, overexpression of RPTPa-Y789F mutant in C-33 LNCaP cells has no effect on ERK activation and fails to induce NE differentiation as well as NSE expression (Figure 7a, b) . The data collectively indicate that NE differentiation induced by RPTPa requires its interaction with downstream molecules as well as PTP activity. Furthermore, the high level of RPTPa expression in androgen-depleted C-33 LNCaP cells as well as in NE subclone cells correlates with those cell proliferations in the absence of androgen. It is thus conceivable that the expression of RPTPa is involved in advanced stage androgen independence as well as NE differentiation of prostate cancer cells. We further hypothesize that RPTPa via c-Src activates the MEK/ERK pathway to promote advanced stage prostate cancer NE differentiation induction as well as androgen independence. This hypothesis is supported by the clinical phenomenon that ERK is highly activated in hormone-refractory prostate tumors (Gioeli et al., 1999) . Together with our previous observations (Meng et al., 2000; Lin et al., 2001; Lee et al., 2003) , it is possible that decreased cellular PAcP expression is involved in the early stage of prostate cancer progression, leading to the early stage of androgen-independent growth and PSA elevation, while elevated RPTPa plays a critical role in advanced stage of NE differentiation in androgen-depleted condition. The molecular mechanism(s), however, require further investigations.
The ERK pathway plays a critical role in the differentiation of various cell types (Fukuda et al., 1995; Ihara et al., 1997; Vossler et al., 1997) . In this study, we also defined the functional role of ERK signaling in NE transdifferentiation of androgen-sensitive C-33 LNCaP cells in androgen-depleted condition, since both ERK1 and ERK2 are highly activated in NE subclone cells. This constitutive activation of ERK is apparently due to the activation of MEK, but not due to the inactivation of MKP. This notion is supported by the observations that PD98059 has no effect on MKP, while it could block androgen depletion-induced acquisition of the NE-like morphology, the activation of ERK, and the elevation of NSE level (Figures 4c, 5) . The role of ERK in NE transdifferentiation is further shown by the expression of a constitutively active MEK mutant in C-33 LNCaP cells. In these cells, constitutive activation of ERK correlates with an increased level of NSE (Figure 8a) . Concurrently, most of those transfected cells acquired the NE-like morphology (Figure 8b ). These results, taken together, suggest that activation of ERK, at least in part due to the elevation of RPTPa, is involved in the NE differentiation of androgen-sensitive prostate cancer cells in an androgendepleted environment.
Although ERK is involved in regulating the differentiation process of various cell lineages, it is possible that other pathways are important as well. In neural differentiation of PC-12 cells induced by bone morphogenic protein-2 or activin A, ERK activation is not required (Iwasaki et al., 1996) . In these studies, our data indicate that other pathways could be involved in the androgen depletion-induced NE differentiation of LNCaP cells. For example, not all MEK cDNAtransfected C-33 LNCaP cells exhibit the NE-like phenotype in the transient transfection experiment. Interestingly, in some NE subclone cells, the p38 MAPK is also activated, as indicated by its phosphorylation at both Thr-180 and Tyr-182, although to a lesser degree than the ERK activation (Zhang and Lin, unpublished data) . This could be biologically interesting, as recent studies indicate that a sustained activation of p38 MAPK is required for different pathways of neuronal differentiation of PC-12 cells (Xia et al., 1995) . Nevertheless, different results were obtained for the p38 MAPK signaling in prostate NE transdifferentiation (Kim et al., 2002) . Further studies are required to determine if p38 MAPK pathway is also involved in the NE-like differentiation of C-33 LNCaP cells.
In PC-12 cells, PKA is required for NGF-induced sustained ERK phosphorylation that results in NE differentiation (Yao et al., 1998) . In prostate cancer cells, db-cAMP treatment can trigger an NE-like phenotype of both androgen-sensitive C-33 and androgen-independent C-81 LNCaP cells . However, db-cAMP has an opposite effect on the expression of NSE in those cells . In the presence of db-cAMP, the NSE level is decreased in C-33 LNCaP cells, while it is elevated in C-81 LNCaP cells. Results of other studies (Cox et al., 1999 (Cox et al., , 2000 showed that the NSE level in LNCaP cells is increased by elevating the cellular cAMP concentration or expressing an active PKA catalytic subunit. One possible explanation is that different growth conditions are utilized. In our experiments, an androgen-depleted condition is used, while an androgen-containing culture condition may have been used for db-cAMP effect in other reports Cox et al., 1999; Deeble et al., 2001) . Alternatively, different LNCaP cells are utilized to induce transdifferentiation. It is possible that high-passage androgen-independent C-81 LNCaP cells were used for those db-cAMP studies, while we used low-passage, androgen-sensitive C-33 LNCaP cells . Our preliminary data showed that PKA inhibitor H-89 cannot efficiently block the androgen depletion-induced NE transdifferentiation of C-33 LNCaP cells (Zhang and Lin, unpublished results) . Further experiments are required to clarify this discrepancy. Although multiple pathways can induce NE transdifferentiation, a common mediator may be involved in facilitating this process. For example, our preliminary results (Zhang and Lin, data not shown) and Chen et al.'s studies showed that ERK is activated in IL-6-treated LNCaP cells. It is thus important to clarify whether ERK is also involved in mediating IL-6-induced NE differentiation of prostate cancer cells (Qiu et al., 1998; Zelivianski et al., 2001) .
In summary, we show here that androgen depletion induces NE-like transdifferentiation of androgen-sensitive C-33 LNCaP human prostate cancer cells via the RPTPa signal pathway (Scheme 1). This transdifferentiation is characterized by a morphological change and an increased expression level of NSE. We show that RPTPa signaling via MEK/ERK is activated in the established NE-like subclone cells induced by androgen depletion. We further determined that RPTPa signaling via ERK is involved in the androgen depletion-induced NE-like differentiation of C-33 LNCaP cells. Thus, ERK plays a critical role in mediating NE transdifferentiation of androgen-sensitive C-33 LNCaP human prostate cancer cells in an androgen-depleted environment, resembling clinical phenomenon. Together with the clinical findings (Gioeli et al., 1999; Price et al., 1999) that ERK is highly activated by hyperphosphorylation in human prostate cancer archival specimens, especially in hormone-refractory carcinomas, compared with normal prostate tissues, the results in this report may have important therapeutic implications.
Materials and methods
Materials
Gentamicin, l-glutamine, FBS, RPMI medium 1640, OPTI-MEM I reduced-serum medium, LipofectAMINE PLUS transfection reagent, and restriction enzymes were purchased from Invitrogen (Carlsbad, CA, USA). Certified charcoal/ dextran-stripped FBS containing testosterone concentration of less than 0.1 nm was from Hyclone (Logan, UT, USA). SDS, glycine, acrylamide/Bis (37.5 : 1) solution, prestained and unstained standard protein markers, and the Coomassie-based protein assay reagent were obtained from Bio-Rad (Hercules, CA, USA). T4 DNA ligase was from Promega (Madison, WI, USA). Mammalian expression vectors pcDNA 3.1 and pTracer-CMV2 were obtained from Invitrogen (Carlsbad, CA, USA). QIAprep Spin Miniprep and QIAGen Maxi plasmid purification kits were obtained from QIAGEN (Valencia, CA, USA). The pSG5 HA-RPTPa WT cDNA, pSG5 RPTPa mutant cDNA with a mutation Tyr789-Phe, and a polyclonal Ab raised against GST protein containing the cytoplasmic domain of murine RPTPa were kind gifts of Dr Tony Hunter (den Hertog et al., 1994; den Hertog and Hunter, 1996; Jiang et al., 1999) . PAcP cDNA was described previously . Anti-ERK Ab was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). MEK1 cDNAs, mouse monoclonal anti-phosphotyrosine (4G10), and anti-NSE Abs were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Polyclonal anti-phospho-ERK (Thr-202/ Tyr-204), anti-phospho-MEK (Ser-217/221), and anti-MEK protein Abs were provided by New England Biolabs (Beverly, MA, USA). Monoclonal anti-HA Ab was from Covance (Richmond, CA, USA). Anti-RPTPa Ab raised against the first phosphatase domain of human RPTPa was purchased from BD Transduction Laboratories (San Diego, CA, USA). Monoclonal anti-b-actin Ab (clone AC-15) was purchased from Sigma. Alexa 594-conjugated goat anti-mouse IgG was kindly provided by Dr Parmender P Mehta. Normal goat serum was purchased from Vector Labs (Burlingame, CA, USA). MEK inhibitor PD98059 was obtained from Calbiochem (La Jolla, CA, USA). SuperSignal West Pico chemiluminescent reagents were from Pierce (Rockford, IL, USA). Casodex was a gift from Astra-Zeneca Pharmaceuticals (Cheshire, UK). Other reagents were purchased from Sigma (St Louis, MO, USA) unless indicated otherwise.
Cell culture and cDNA transfection
Human prostate cancer cell line LNCaP was purchased originally from the American Type Culture Collection (Manassas, VA, USA) and maintained in the regular culture medium, that is, phenol red-positive RPMI 1640 medium supplemented with 5% FBS, 1% glutamine, and 0.5%. gentamicin (Lin et al., 1992) . Cells were trypsinized once a week as one passage. For experiments, cells with passage numbers between 25 and 33, which retained their androgen sensitivity and were designated as C-33 LNCaP cells , were utilized. The liposome-mediated cDNA transfection was performed using LipofectAMINE PLUS reagent. Cells were plated and maintained in six-well plates or 100-mm culture dishes for 40 h. An aliquot of 1 and 6 mg plasmids carrying proper cDNAs was used for transfection of the cells in each well and dish, respectively. Cells were harvested after transfection at the time period specified in the description of each experiment.
Establishment of NE subclone cells
LNCaP cells were initially seeded in the regular culture medium. Subsequently, the cells were maintained in a steroid-reduced medium, that is, phenol red-free RPMI 1640 containing 5% heat-inactivated, charcoal/dextran-stripped FBS, 1% glutamine, and 0.5% gentamicin . Under this condition, the cell growth diminished, and the morphology of LNCaP cells changed gradually. The population of NE-like cells was maintained continuously in the steroid-depleted medium and the single cell was isolated by a cylinder and propagated. After approximately 4-6 months, several subclone cells became independent cell lines.
Determination of protein concentration
Protein concentration was determined using the Bio-Rad Protein Assay reagent. Bovine serum albumin was used as the reference.
Scheme 1 Proposed mechanism of NE transdifferentiation from androgen-sensitive LNCaP cells in an androgen-depleted condition. Androgen-sensitive prostate cancer cells under the androgendepleted condition express an elevated level of RPTPa, which can activate MEK and ERK, leading to an altered phenotype and increased expression of NSE. Consequently, androgen-sensitive LNCaP cells transdifferentiate into NE-like cells
SDS-PAGE and Western blotting
Proteins in total cell lysates were separated by SDS-PAGE and then electrophoretically transferred to nitrocellulose membranes (Micron Separation, MA, USA). To increase the transferring efficiency of high molecular weight proteins, 0.1% SDS was included in the blotting buffer Meng and Lin, 1998; Zhang et al., 2001) . The nitrocellulose membranes were probed with appropriate primary and horseradish peroxidase-conjugated secondary Abs. Specific proteins on the membrane were visualized using the SuperSignal West Pico chemiluminescent reagents.
Expression of GFP
To determine the effect of RPTPa on inducing NE-like morphology, C-33 LNCaP cells were plated on glass coverslips and cotransfected with 0.25 mg GFP vector pTracer-CMV2 plus 1 mg pSG5-RPTPa wild-type or pSG5-RPTPa-Y789F mutant cDNA. To examine the effect of MEK on inducing NE-like morphology, C-33 LNCaP cells were transfected with an HA-tagged rat wild-type or activated (S218D/S222D double mutant) MEK cDNA which was subcloned into KpnI/XbaI of the GFP vector pTracer-CMV2. After transfection, cells were then fixed with 2% paraformaldehyde or cold methanol and visualized with a Nikon ECLIPSE E800 microscope.
Immunofluorescence staining
Cells were plated on glass coverslips and maintained in corresponding conditions for 72 h. After washing with PBS, cells were fixed with 2% paraformaldehyde and permeabilized by 0.2% Triton X-100 in PBS for 30 min. After blocking with normal goat serum, fixed cells were incubated with a monoclonal anti-NSE Ab (1 : 50 dilution) for 1 h at room temperature (RT). Control staining was performed without primary Ab or incubating with normal IgG. After three washes with PBS containing 0.25% Tween-20, cells were incubated for 30 min at RT with secondary Ab, that is, Alexa 594-conjugated goat anti-mouse IgG. Fluorescence was visualized with the Zeiss LSM 410 confocal laser scanning microscope (Goettinger, Germany) with Â 400 magnification.
Abbreviations NE, neuroendocrine; NSE, neuron-specific enolase; cAMP, adenosine 3 0 ,5 0 -cyclic monophosphate; db-cAMP, dibutyrate cAMP; PKA, protein kinase A; PI3K, phosphatidylinositol 3-kinase; IL, interleukin; ERK, extracellular signal-regulated kinase; MEK, ERK kinase; MAPK, mitogen-activated protein kinase; MKP, ERK/MAPK phosphatase; NGF, nerve growth factor; HA, hemagglutinin; FBS, fetal bovine serum; SR-FBS, steroid-reduced FBS; ECL, enhanced chemiluminescence; GFP, green fluorescent protein; PTP, protein tyrosine phosphatase; RPTPa, receptor protein tyrosine phosphatase alpha; DHT, 5a-dihydrotestosterone; Ab, antibody.
